Ceftriaxone Sodium

ApprovedSmall molecule

Pfizer

Ceftriaxone Sodium is one of 62 small molecule programs targeting Malnutrition. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalnutritionActive, not recruiting

SyphilisActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

MalnutritionPhase 2/Phase 3

Active, not recruiting

SyphilisPreclinical

Active, not recruiting

Hepatocellular CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ceftriaxone Sodium

Pfizer

Approved

1 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Coreg

Akero Therapeutics

Preclinical

2 6

Opdivo

Bristol-Myers Squibb

Preclinical

2 7

Statin

Bristol-Myers Squibb

Preclinical

1 8

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

PD-1 Inhibitors

5 10

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Antibiotics1 trial

Assessing Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration for Prevention of SSI

Withdrawn·TThe Grant Medical College & Sir J.J. Group of Hospitals·Phase 4·NCT04975945

Malnutrition1 trial

Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition

Unknown status·MMakerere University·Phase 2/3·NCT05051163·300 enrolled

Advanced or Metastatic Solid Tumors1 trial

VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy

Completed·VVion Pharmaceuticals·Phase 1·NCT00004216

Syphilis1 trial

A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000648·100 enrolled

Hepatocellular Carcinoma1 trial

Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma

Unknown status·NNadeem Iqbal·Phase 3·NCT05654896·158 enrolled

4 more indications

Prospective1 trial

Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients

Completed·UUniversity of Southern California·N/A·NCT00002052

Intravenous1 trial

A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection

Completed· Pfizer logo

Pfizer·Phase 3·NCT01473836·38 enrolled

Injury1 trial

Mecobalamin Combined With Ceftriaxone Sodium in the Treatment of Sepsis Liver Injury

Unknown status·SSichuan Provincial People's Hospital·Phase 4·NCT06220929·40 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01254344·599 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Ceftriaxone Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ceftriaxone Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ceftriaxone Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Ceftriaxone Sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Antibiotics1 trial

Malnutrition1 trial

Advanced or Metastatic Solid Tumors1 trial

Syphilis1 trial

Hepatocellular Carcinoma1 trial

Prospective1 trial

Intravenous1 trial

Injury1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News